A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation

Pediatric Transplantation

Volumn 9, Issue 3, 2005, Pages 282-292

  Benfield, Mark R ^a   Tejani, Amir ^b   Harmon, William E ^c,g   McDonald, Ruth ^d   Stablein, Donald M ^e   McIntosh, Matthew ^e   Rose, Stephen ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e EMMES CORPORATION   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g NAPRTCS   (United States)

Author keywords

Immunosuppression; Induction; Monoclonal antibody; Pediatric transplantation; Rejection; Renal function; Renal transplant

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CREATININE; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; MYCOPHENOLIC ACID; PREDNISONE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 20344364670     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00296.x     Document Type: Article

References (19)

1. BENFIELD MR, MCDONALD RA, BARTOSH SM, HO PL, HARMON WE. Changing trends in pediatric transplantation: 2001 Annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002: 7: 321-335.
2. MCDONALD R, DONALDSON L, EMMETT L, TEJANI A. A decade of living donor transplantation in North American children: the 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000: 4: 221-234.
3. ELSHIHABI I, CHAVERS B, DONALDSON L, EMMETT L, TEJANI A. Continuing improvement in cadaver donor graft survival in North American children: the 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000: 4: 235-246.
4. BENVENISTY AI, COHEN D, STEGALL MD, HARDY MA. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990: 49: 321-327.
5. HANTO DW, JENDRISAK MD, SO SK, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 1994: 57: 377-384.
6. KAHANA L, ACKERMANN J, LEFOR W, et al. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation. Transplant Proc 1990: 22: 1755-1758.
7. NORMAN DJ, KAHANA L, STUART FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993: 55: 44-50.
8. BACCHUS WM, HOEDEMAEKER PJ, ROZING J, BAKKER WW. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 1986: 55: 680-687.
9. RAAFAT R, TRAVIS LB, KALIA A, DIVEN S. Role of transplant induction therapy on recurrence rate of focal segmental glomerulosclerosis. Pediatr Nephrol 2000: 14: 189-194.
10. OKUDA S, LANGUINO LR, RUOSLAHTI E, BORDER WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990: 86: 453-462.
11. [erratum appeared in J Clin Invest 1990 Dec;86(6):2175]
12. SHARMA VK, BOLOGA RM, XU GP, et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996: 49: 1297-1303.
13. BENFIELD MR, MCDONALD R, SULLIVAN EK, STABLEIN D, TEJANI A. The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999: 3: 152-167.
14. KIRK AD, BURKLY LC, BATTY DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999: 5: 686-693. [comment]
15. DHARNIDHARKA VR, SULLIVAN EK, STABLEIN DM, TEJANI AH, HARMON WE, North American Pediatric Renal Transplant Cooperative Study. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study(NAPRTCS). Transplantation 2001: 71: 1065-1068.
16. OPELZ G, HENDERSON R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993: 342: 1514-1516. [comment]
17. SOLLINGER HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995: 60: 225-232.
18. Anonymous. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995: 345: 1321-1325. [comment]
19. Anonymous. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996: 61: 1029-1037. [comment]